Clinical Trials · NCT01786265
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 310
- Start date
- Feb 2013
- Locations
- 1 site, United States
- Primary endpoint
- Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml)